Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 232

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 232
---
 Pharma A/S, Cycle Pharma and ASP Isotopes. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the Peoples Republic of China. We believe that Dr. Moore is qualified to serve on our Board of Directors because of his experience, attributes and skills, including his extensive pharmaceutical and executive experience. B. Compensation Compensation of Directors and Executive Officers For the year ended December 31, 2024, the aggregate compensation paid to the members of our Board of Directors and our executive officers for services in all capacities, including retirement and similar benefits, was $3.4 million. During the year ended December 31, 2024, GH Research PLC granted options to purchase an aggregate of 1,043,120 ordinary shares to directors and executive officers. 60,000 of these share options were granted to a number of executive officers which vest 25% on the first anniversary of the date of grant, and thereafter in equal installments on a monthly basis over the subsequent three years and are subject to a two-year service condition. The contractual term (expiration) of these share options is eight years from the grant date with a weighted-average exercise price of $6.84. 33,120 of these share options were granted to members of our Board of Directors which were fully vested on the date of grant and are subject to a two-year service condition. The contractual term (expiration) of these share options is seven years from the grant date with a weighted-average exercise price of $0.025. 950,000 of these share options were granted to members of our Board of Directors and executive officers which vest 25% on the first anniversary of the date of grant, and thereafter in equal installments on a monthly basis over the subsequent three years. The contractual term (expiration) of these share options is seven years from the grant date with a weighted-average exercise price of $0.025. 140 Table of Contents Equity Incentive Plans Share Option Plan We have adopted a share option plan (referred to herein as the Share Option Plan), under which grants of options are made to eligible participants. The purpose of the Share Option Plan is to attract, retain and motivate employees and directors to provide for competitive compensation opportunities, to encourage long term service, to recognize individual contributions and reward achievement of performance goals, and to promote the creation of long term value for our shareholders. In 2024, our Board of Directors approved an